Navigation Links
Syndax Pharmaceuticals Appoints Arlene Morris as CEO
Date:4/18/2012

WALTHAM, Mass., April 18, 2012 /PRNewswire/ -- Syndax Pharmaceuticals, Inc., an oncology company moving into phase 3 having completed randomized, placebo controlled phase 2 studies, announced the appointment of Arlene M. Morris as chief executive officer.  Joanna Horobin, MD will serve as president. 

"Syndax is leading the field of epigenetics—a novel way to control gene regulation—to address unmet needs in cancer due to the problem of resistance," said Dennis Podlesak, chairman of the Syndax board of directors. "With the positive phase 2 randomized, placebo-controlled data and the addition of Arlene Morris to our impressive leadership team, Syndax is well positioned to successfully complete the final phase of clinical development to achieve our goal of providing a new treatment option for women with metastatic breast cancer."

During her eight years as president and CEO at Affymax, Ms. Morris led the company through the development of peginesatide (Omontys®), a strategic collaboration with Takeda and an Initial Public Offering. Prior to Affymax Ms. Morris was the president and CEO of Clearview Projects, an advisory firm which counseled biopharmaceutical and biotechnology companies on strategic transactions. Before that she was the senior vice president, business development at Coulter, a biotechnology company focused on immunotherapeutic approaches to cancer, autoimmune and infectious diseases, where she completed numerous transactions including a $1.0 billion merger between Corixa and Coulter. Ms. Morris began her career at Johnson & Johnson (J&J) as a sales representative rising to vice president of business development. Ms. Morris received her bachelor's degree in biology and chemistry from Carlow College. In addition to Syndax Ms. Morris serves on the board of directors of Neovacs and MediciNova.

"After working with Syndax as a director over the past nine months, I am excited to take a more active role now as we move entinostat forward and secure the financing and personnel required to take this exciting product candidate for breast cancer through the final phase of testing," said Ms. Morris. 

About Syndax
Syndax is a late-stage oncology company supported by top venture capitalists and led by industry experts developing treatments for large markets including metastatic breast and lung cancer. The Company's platform is based on employing epigenetics to overcome the problem of resistance in oncology care. Syndax holds worldwide rights to entinostat, an oral, highly selective histone deacetylase (HDAC) inhibitor, which inhibits cancer-relevant HDAC enzymes which contribute to epigenetic alterations driving cancer growth and drug tolerance. Entinostat's unique pharmacokinetic properties, convenient oral dosing and HDAC selectivity, maximize the opportunity to safely combine with and potentially extend the benefit of proven cancer therapies. Entinostat has demonstrated promising activity in randomized, phase 2 clinical trials in combination with targeted therapies.   For more information please visit www.syndax.com.

Contact Information
E. Blair Schoeb   
Syndax Pharmaceuticals, Inc.                                                     
Tel: 908.277.0386                                                                             
bschoeb@syndax.com 


'/>"/>
SOURCE Syndax Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
2. Syndax Pharmaceuticals to Present at Upcoming Fall Conferences
3. Syndax Pharmaceuticals Announces Issuance of EU Patent for Entinostat
4. Syndax Pharmaceuticals to Present at BIO Investor Forum
5. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
6. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2011 Financial Results on March 12, 2012
7. Onyx Pharmaceuticals to Present at Upcoming Investor Conferences
8. Avanir Pharmaceuticals to Participate in Citi 2012 Global Health Care Conference
9. Swedish Bactiguard to Enter Into an Exclusive Distribution Agreement With Cadila Pharmaceuticals
10. BioDelivery Sciences Receives Patent Allowance Triggering $15 Million Milestone Payment from Endo Pharmaceuticals
11. Questcor Pharmaceuticals to Present at the Leerink Swann Global Healthcare Conference on February 16, 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/12/2016)... SAN FRANCISCO , February 12, 2016 /PRNewswire/ ... Precision Medicine Efforts by Enabling Scientific Understanding of ... Disorders and Rare Diseases --> ... for genomic diagnostics in South Asia and a leading ... it would contribute $10 million to the GenomeAsia ...
(Date:2/11/2016)... Germany and GERMANTOWN, ... QGEN ; Frankfurt Prime Standard: QIA) today announced ... RNA Panels for gene expression profiling, expanding QIAGEN,s portfolio ... The panels enable researchers to select from over 20,000 ... and discover interactions between genes, cellular phenotypes and disease ...
(Date:2/11/2016)... NY (PRWEB) , ... February ... ... a business-to-business publication dedicated to delivering cutting-edge information focused on the development ... Life Sciences to become a premier sponsor of the 2016 BioProcess International ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... 150 years, continues today to pursue the highest level of accuracy and quality ... the AR9 Refractometer and the AR5 Refractometer. Accurate, reliable and tough enough ...
Breaking Biology Technology:
(Date:2/9/2016)... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... fourth quarter and year ended December 31, 2015.  ... of 2015 was $6.9 million, an increase of 61% compared to ... the fourth quarter of 2015 was $2.6 million compared to $0.2 ... --> --> Higher revenue and operating income in ...
(Date:2/3/2016)... Sweden , February 4, 2016 --> ... amounted to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter ... profit amounted to SEK 517.6 M (loss: 30.0). Earnings per ... operating activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared ...
(Date:2/2/2016)... 2016 This BCC Research report provides ... reviewing the recent advances in high throughput ‘omic ... field forward. Includes forecast through 2019. ... and opportunities that exist in the bioinformatic market. ... as well as IT and bioinformatics service providers. ...
Breaking Biology News(10 mins):